2-[[(4-甲氧基-1-萘基)氧基]甲基]环氧乙烷 | 14133-78-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-[[(4-甲氧基-1-萘基)氧基]甲基]环氧乙烷
• 中文别名: 2-{[(4-甲氧基萘-1-基)氧代]甲基}噁丙环
• 英文名称: 1-Methoxy-4-(2,3-epoxy)propoxynaphthalene
• 英文别名: 2-[[(4-Methoxy-1-naphthalenyl)oxy]methyl]oxirane；2-[(4-methoxynaphthalen-1-yl)oxymethyl]oxirane
• CAS: 14133-78-9
• 化学式: C₁₄H₁₄O₃
• 分子量: 230.263
• InChiKey: AVLUBEJQNBBJCK-UHFFFAOYSA-N

物化性质

• 沸点：
  392.5±12.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  31
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2910900090

反应信息

• 作为反应物：
  描述：

  2-[[(4-甲氧基-1-萘基)氧基]甲基]环氧乙烷 、 异丙胺 反应 2.0h， 生成 4-甲氧基普萘洛尔
  参考文献：
  名称：

  4-甲氧基普萘洛尔的合成，一种适用于通过 HPLC 测定普萘洛尔和 4-羟基普萘洛尔的内标

  摘要：

  描述了4-甲氧基心得安的合成。中间体和最终产品的结构通过通常的光谱方法得到保证。

  DOI：

  10.1002/ardp.19813140510
• 作为产物：
  描述：

  4-甲氧基-1-萘酚 生成 2-[[(4-甲氧基-1-萘基)氧基]甲基]环氧乙烷
  参考文献：
  名称：

  OATIS J. E. JR.; RUSSEL M. P.; KNAPP D. R.; WALLE T., J. MED. CHEM., 1981, 24, NO 3, 309-314

  摘要：

  DOI：

文献信息

• Calcilytic compounds
  申请人：Del Mar G. Eric

  公开号：US20050032850A1

  公开（公告）日：2005-02-10

  The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

  本发明涉及钙解离化合物。 "钙解离化合物"是指能够抑制钙受体活性的化合物。还描述了使用钙解离化合物来抑制钙受体活性和/或在患者中获得有益效果的方法；以及可用于获得其他钙解离化合物的技术。
• CALCILYTIC COMPOUNDS
  申请人：Del Mar Eric G.

  公开号：US20070249702A1

  公开（公告）日：2007-10-25

  The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

  本发明涉及钙解离化合物。 “钙解离化合物”是指能够抑制钙受体活性的化合物。同时，本发明还描述了使用钙解离化合物来抑制钙受体活性和/或在患者中获得有益效果的方法；以及可用于获得其他钙解离化合物的技术。
• .beta.-Adrenergic blocking agents. II. Propranolol and related 3-amino-1-naphthoxy-2-propanols
  作者：A. F. Crowther、L. H. Smith

  DOI：10.1021/jm00311a021

  日期：1968.9
• Ring-hydroxylated propranolol: synthesis and .beta.-receptor antagonist and vasodilating activities of the seven isomers
  作者：J. E. Oatis、M. P. Russell、D. R. Knapp、T. Walle

  DOI：10.1021/jm00135a014

  日期：1981.3

  Propranolol (Inderal; 1) is extensively metabolized in man. Metabolites of interest pharmacologically include ring-hydroxylated propranolols (1a-g). In order to identify these ring-oxidized products and to study the effect of hydroxyl position on biological activity, we have synthesized all seven isomers. With the exception of 1b and 1g, the desired compounds were prepared by alkylation of the respective methoxy-1-naphthols with epichlorohydrin and reaction of the resulting epoxide with isopropylamine. Cleavage og the methyl group in fused pyridine hydrochloride afforded 1a,c-f. 1g was prepared by the direct alkylation of 1,8-naphthalenediol (17) with epichlorohydrin, followed by reaction with isopropylamine. 1b was synthesized by treating 2-naphthol (9) with chlorine gas and then treating the resulting 1,1-dichloronaphthalen-2(1H)-one (10) with sodium allyl oxide. Acetylation of the hydroxy function and epoxidatrion of the allyl group, followed by relation with isopropylamine, gave 3'-hydroxy-4'-chloropropranolol (15). Dechlorination gave 1b. All of the racemic hydroxylated propranolols produced beta blockade and direct vasodilation in anesthetized dogs. The potency is strongly dependent upon the position of the hydroxyl group, i.e., 1e is 4 times as potent as 1 as a beta receptor antagonist, whereas 1a, 1b, and 1g are all significantly less potent than 1. For direct vasodilation, 1a and 1g are equipotent to 1, while 1b-f are much less potent. The potencies of the compounds were also compared with their 1-octanol/pH 7.4 buffer distribution coefficients; the direct vasodilating potency was found to increase with increasing lipophilicity, while the beta-adrenergic antagonist potency decreased.
• REMON J.-P.; GYSELINCK P.; SYNAVE R.; SEVEREN R. VAN; BRAECKMANN P., ARCH. PHARM., 1981, 314, NO 5, 432-435
  作者：REMON J.-P.、 GYSELINCK P.、 SYNAVE R.、 SEVEREN R. VAN、 BRAECKMANN P.

  DOI：——

  日期：——